Matinas BioPharma Holdings, Inc.
MTNB
$0.18
$0.000.93%
AMEX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -100.00% | -100.00% | -99.26% | -80.65% | -65.89% |
| Gross Profit | 100.00% | 100.00% | 99.26% | 80.65% | 65.89% |
| SG&A Expenses | -11.12% | -14.55% | -21.23% | -25.31% | -24.87% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -45.35% | -57.11% | -65.48% | -57.30% | -48.65% |
| Operating Income | 45.35% | 57.11% | 65.48% | 57.30% | 48.65% |
| Income Before Tax | 66.02% | 47.38% | 57.48% | 19.81% | 14.07% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 65.88% | 47.17% | 57.34% | 20.19% | 14.42% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 65.88% | 47.17% | 57.34% | 20.19% | 14.42% |
| EBIT | 45.35% | 57.11% | 65.48% | 57.30% | 48.65% |
| EBITDA | 44.49% | 56.48% | 65.01% | 57.12% | 48.72% |
| EPS Basic | 68.76% | 48.95% | 58.81% | 25.20% | 24.31% |
| Normalized Basic EPS | 53.60% | 60.78% | 67.82% | 59.61% | 52.82% |
| EPS Diluted | 68.76% | 48.95% | 58.81% | 25.20% | 24.31% |
| Normalized Diluted EPS | 53.60% | 60.78% | 67.82% | 59.61% | 52.82% |
| Average Basic Shares Outstanding | 20.84% | 14.91% | 12.50% | 10.58% | 12.62% |
| Average Diluted Shares Outstanding | 20.84% | 14.91% | 12.50% | 10.58% | 12.62% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |